Atossa Therapeutics (ATOS) Revenue & Revenue Breakdown
Atossa Therapeutics Revenue Highlights
00
Atossa Therapeutics Revenue by Period
Atossa Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | -100.00% |
| 2015-12-31 | $1.76K | -99.67% |
| 2014-12-31 | $525.95K | -16.85% |
| 2013-12-31 | $632.56K | 31.28% |
| 2012-12-31 | $481.84K | 32022.80% |
| 2011-12-31 | $1.50K | 100.00% |
| 2010-12-31 | - | - |
Atossa Therapeutics generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Atossa Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $18.00K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | -100.00% |
| 2015-12-31 | $-5.34M | -791.22% |
| 2015-09-30 | $772.24K | -71.34% |
| 2015-06-30 | $2.69M | 43.82% |
| 2015-03-31 | $1.87M | 283.45% |
| 2014-12-31 | $488.53K | 14159.46% |
| 2014-09-30 | $3.43K | -65.31% |
| 2014-06-30 | $9.88K | -59.07% |
| 2014-03-31 | $24.12K | -48.90% |
| 2013-12-31 | $47.21K | -38.36% |
| 2013-09-30 | $76.60K | -76.51% |
| 2013-06-30 | $326.08K | 78.51% |
| 2013-03-31 | $182.67K | 85.53% |
| 2012-12-31 | $98.46K | -6.74% |
| 2012-09-30 | $105.58K | -52.68% |
| 2012-06-30 | $223.10K | 476.97% |
| 2012-03-31 | $38.67K | 2477.80% |
| 2011-12-31 | $1.50K | 100.00% |
| 2011-09-30 | - | 100.00% |
| 2011-06-30 | - | 100.00% |
| 2011-03-31 | - | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2010-09-30 | - | 100.00% |
| 2010-06-30 | - | 100.00% |
| 2009-09-30 | - | - |
Atossa Therapeutics generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Atossa Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| NVAX | Novavax | $983.71M | $415.48M |
| INO | Inovio Pharmaceuticals | $832.01M | - |
| JAGX | Jaguar Health | $9.76M | $3.07M |
| TNXP | Tonix Pharmaceuticals | $7.77M | $2.82M |
| VXRT | Vaxart | $7.38M | $4.93M |
| OCGN | Ocugen | $6.04M | $1.14M |
| PALI | Palisade Bio | $250.00K | - |
| SONN | Sonnet BioTherapeutics | $147.81K | - |
| ELEV | Elevation Oncology | - | - |
| GOVX | GeoVax Labs | - | $300.68K |
| ATOS | Atossa Therapeutics | - | - |
| OCEA | Ocean Biomedical | - | - |
| ENVB | Enveric Biosciences | - | - |